Innovative Medicines Initiative (IMI) Case Study Analysis Reveals the True Added Value of Early-Phase Public-Private Partnerships (PPPs)

Biotechnology Law Report - United States
doi 10.1089/blr.2015.29008.hs
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Mary Ann Liebert Inc

Related search

Public-Private Partnerships as Driving Forces in the Quest for Innovative Medicines

Clinical and Translational Medicine
MedicineMolecular Medicine
2013English

Boosting Drug Development Through Public-Private Partnerships – The IMI Model

EPMA Journal
BiochemistryHealth PolicyDrug Discovery
2014English

Financing Development Through Public Private Partnerships (PPPs) in Botswana

Africa’s Public Service Delivery and Performance Review
2016English

Public-Private Partnerships (PPPs) in Development Policy: Exploring the Concept and Practice

Development Policy Review
DevelopmentManagementMonitoringPlanningPolicyLawGeography
2018English

The Governance Structure for Data Access in the DIRECT Consortium: An Innovative Medicines Initiative (IMI) Project

Life Sciences, Society and Policy
ManagementMonitoringMolecular BiologyBiochemistryPhilosophyPolicyGeneticsLaw
2018English

The Real Option Value of Renegotiation in Public–Private Partnerships

Journal of Construction Engineering and Management - ASCE
BuildingIndustrial RelationsManagementCivilStructural EngineeringStrategyConstruction
2016English

Public-Private Partnerships and the Public Accountability Question

Public Administration Review
MarketingSociologyPolitical SciencePublic Administration
2010English

Krka′s Cardiovascular Medicines – Value-Added Generic Medicines.

Cardiologia Croatica
Cardiovascular MedicineCardiology
2015English

The Strategic Case for Establishing Public-Private Partnerships in Cancer Care

Health Research Policy and Systems
MedicineHealth Policy
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy